Replimune Group (NASDAQ:REPL – Get Free Report) posted its earnings results on Wednesday. The company reported ($0.54) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.78) by $0.24, FiscalAI reports.
Here are the key takeaways from Replimune Group’s conference call:
- TUDRIQEV’s launch is showing early traction: More than 70% of the initial 200 target accounts have been engaged, approximately 20 have added the drug to formulary, and more than 15 institutions had written prescriptions within the first 20 business days.
- Replimune reported strong physician interest across academic, community, oncology, and interventional radiology settings, with both superficial and image-guided injections already being used. Management expects the number of accounts initiating patients could potentially double by year-end.
- Coverage appears to be broad and favorable: TUDRIQEV has a Category 2A NCCN recommendation, Medicare coverage, and commercial payer policies covering its label—including retreatment in appropriate cases—with a permanent J-code expected by April 2027.
- The company reported no product revenue in the fiscal second quarter because commercial shipments began in October; it will report initial product revenue in the fiscal third quarter but is not providing revenue guidance. TUDRIQEV’s list price is $450,000 per treatment course before discounts, with revenue recognized over multiple quarters in some cases.
- Replimune ended the quarter with $307.8 million in cash, including $141 million from an August offering, and expects funding to support operations for more than 12 months while investing in the launch, IGNYTE-3, and the REVEAL uveal melanoma study.
Replimune Group Trading Up 16.0%
NASDAQ:REPL traded up $2.08 during mid-day trading on Wednesday, reaching $15.13. 2,513,042 shares of the company’s stock traded hands, compared to its average volume of 4,305,551. Replimune Group has a 12-month low of $1.50 and a 12-month high of $16.33. The firm has a market capitalization of $1.42 billion, a price-to-earnings ratio of -4.77 and a beta of 0.93. The company has a debt-to-equity ratio of 1.00, a current ratio of 5.23 and a quick ratio of 5.23. The company has a 50 day moving average price of $13.45 and a 200-day moving average price of $9.21.
Analyst Upgrades and Downgrades
Several research firms have weighed in on REPL. Wolfe Research raised Replimune Group to an “outperform” rating in a report on Tuesday, August 4th. Cantor Fitzgerald reissued an “overweight” rating on shares of Replimune Group in a research note on Monday, October 5th. Wedbush upgraded shares of Replimune Group from a “neutral” rating to an “outperform” rating and set a $12.00 price objective for the company in a report on Friday, August 7th. JPMorgan Chase & Co. upped their price objective on shares of Replimune Group from $20.00 to $21.00 and gave the company an “overweight” rating in a research note on Wednesday, August 26th. Finally, Leerink Partners raised shares of Replimune Group from a “market perform” rating to an “outperform” rating and increased their target price for the company from $11.00 to $17.00 in a report on Tuesday, August 4th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has given a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $12.00.
View Our Latest Research Report on Replimune Group
Insiders Place Their Bets
In related news, CFO Emily Hill sold 9,256 shares of the company’s stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $14.28, for a total transaction of $132,175.68. Following the completion of the transaction, the chief financial officer owned 215,852 shares in the company, valued at $3,082,366.56. This represents a 4.11% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CAO Andrew Schwendenman sold 7,632 shares of the firm’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $12.97, for a total value of $98,987.04. Following the completion of the sale, the chief accounting officer directly owned 99,425 shares of the company’s stock, valued at $1,289,542.25. The trade was a 7.13% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders have sold 79,124 shares of company stock worth $1,038,364. Corporate insiders own 5.40% of the company’s stock.
Replimune Group Company Profile
Replimune Group, Inc is a clinical-stage biotechnology company developing cancer immunotherapies designed to stimulate the immune system to recognize and attack tumors. The company’s approach focuses on oncolytic immunotherapy, using genetically engineered viruses intended to selectively infect and destroy tumor cells while also activating broader antitumor immune responses.
Replimune’s lead product candidate is RP1, also known as vusolimogene oderparepvec, an engineered oncolytic herpes simplex virus type 1 designed to replicate within tumors and promote systemic immune activity.
Read More
- Five stocks we like better than Replimune Group
- Amkor’s Mobile Business Is Slowing, But Its AI Ambitions Aren’t
- Want to Own a Piece of Professional Sports? This ETF Could Be Your Ticket
- Welltower’s Strong Earnings Couldn’t Stop the Sell-Off—What’s Missing?
- Sherwin-Williams Remains Evergreen in a Frozen Housing Market
Receive News & Ratings for Replimune Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Replimune Group and related companies with MarketBeat.com's FREE daily email newsletter.
